The purpose of this study was to evaluate one versus two doses of local delivery cisplatin in a biodegradable polymer (OPLA-Pt) for the treatment of osteosarcoma (OSA) after amputation in dogs.
Medical records were reviewed retrospectively, and 105 dogs were included in the study; 39% of dogs received one treatment (surgical implantation) of OPLA-Pt and 61% of dogs received two treatments of OPLA-Pt after amputation.
Administration of two doses of OPLA-Pt did not have a significant effect on disease-free interval or survival time compared to one dose.
The anatomic site of the tumour was identified as a prognostic factor, and dogs with proximal humeral OSA had the shortest disease-free interval and survival times.
There was no advantage to giving a second dose of local delivery cisplatin following amputation for the treatment of OSA in dogs.
Source: Mehl, M. L., Seguin, B., Dernell, W. S., Lafferty, M., Kass, P. H. & Withrow, S. J. (2005):
Survival analysis of one versus two treatments of local delivery cisplatin in a biodegradable polymer for canine osteosarcoma. In: Veterinary and Comparative Oncology 3 (2), 81-86.
Tell a friend
|
Print version
|
Send this article
|
